Lupin buys Gavis Pharmaceuticals and gains first US facility

By Gareth Macdonald contact

- Last updated on GMT

Lupin's US manufacturing facility in Somerset, New Jersey (source Google)
Lupin's US manufacturing facility in Somerset, New Jersey (source Google)

Related tags: Food and drug administration

Lupin acquired drug formulation developer Gavis Pharmaceuticals this week in a deal that gives it its first manufacturing site in the US.

The facility in New Jersey is operated by Gavis’ subsidiary, Novel Laboratories.

It is equipped to manufacture and store schedule II to V drugs and undertake solvent-based production processes. According to Gavis the site has passed three US Food and Drug Administration (FDA) inspections.

BMI Research said in a note to investors that: "Gavis' US-based R&D organisation would complement Lupin's Coral Spring, FL, inhalation R&D centre​."

In addition to the manufacturing plant, the takeover gives Lupin a combined portfolio of 120 US-approved generic drugs and 185 pending ANDA applications, including 45 first-to-file (FTF) products offering 180 day market exclusivity.

Caveats

The takeover was approved by the US Federal Trade Commission (FTC) last month​ on the condition Gavis sold assets for two generic products - doxycycline monohydrate and mesalamine ER – to rival G&W.

Gavis was also required to transfer manufacturing technology for doxycycline and to produce it on G&W’s behalf for a two-year interim period.

Similarly, Gavis must make mesalamine for G&W and give the firm access to knowledgeable production staff to allow the firm to seek FDA approval for the product.

Completion of the $850m (€744m) deal follows days after Lupin confirmed it plans to build a generic drug manufacturing facility in Tottori​, Japan to try and capture a greater share of the country’s growing non-branded drug market.

Business dynamics

Completion of the Gavis takeover also comes a few weeks after Lupin published financial results that illustrated the growing importance finished drug products to its business.

Total revenue the third quarter of FY16 increased 11.9% to INR35.6bn ($54 0 .5m) with the contribution from formulations – finished drug products – growing 7.4% year on year to INR30.82bn.

Lupin’s active pharmaceutical ingredient (API) business – which is founded on key products like cephalosporin antibiotics and cardiovascular and anti-TB drug actives - generated revenue of INR2.76bn, which is just 0.1% higher than in fiscal 2015.

Related news

Show more

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us

Products

View more

Webinars